Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

• Cassandra Rayer,
• Maria Nachury,
• Arnaud Bourreille,
• Xavier Roblin,
• Laurent Peyrin-Biroulet,
• Stephanie Viennot,
• Mathurin Flamant,
• David Laharie,
• Bénédicte Caron,
• Marie Dewitte,
• Laurent Siproudhis,
• Mathurin Fumery,
• Guillaume Bouguen

Affiliations

Cassandra Rayer

CHU Rennes, University Rennes

Maria Nachury

CHU Lille, University of Lille

Arnaud Bourreille

CHU Nantes

Xavier Roblin

CHU Saint-Etienne

Laurent Peyrin-Biroulet

Inserm U954 Deparment of Hepato-Gastroenterology, Department of Gastroenterology, Nancy University Hospital

Stephanie Viennot

CHU Caen

Mathurin Flamant

Clinique Jules Vernes

David Laharie

CHU de Bordeaux, Hôpital Haut-Lévêque, Service d’Hépato-Gastroentérologie Et Oncologie Digestive, Université de Bordeaux

Bénédicte Caron

Inserm U954 Deparment of Hepato-Gastroenterology, Department of Gastroenterology, Nancy University Hospital

Marie Dewitte

CHU Rennes, University Rennes

Laurent Siproudhis

CHU Rennes, University Rennes, INSERM, CIC1414, Institute NUMECAN (Nutrition Metabolism and Cancer)

Mathurin Fumery

Service d’Hépato-Gastroentérologie Et Oncologie Digestive, CHU Amiens Et PeriTox, UMR I0-I, Université de Picardie

Guillaume Bouguen

CHU Rennes, University Rennes, INSERM, CIC1414, Institute NUMECAN (Nutrition Metabolism and Cancer)